logo

For the Inventor, By the Inventor

South Hamilton, MA, United States of America

David Fabrizio

This inventor holds 18 USPTO granted patents and 5 published patent applications and 7 EPO patents, primarily in Targeted Therapeutics. Top assignee: Bristol-Myers Squibb Compnay. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David Fabrizio. Retrieved from https://idiyas.com/inventor/david-fabrizio

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 18 

% Patents Active = 100.0

 

Average Co-Inventor Count = 6.5

ph-index = 8

Forward Citations = 238(Granted Patents)


Location History:

  • Swampscott, MA (US) (2013 - 2015)
  • South Hamilton, MA (US) (2016 - 2022)

Company Filing History:

goldMedal18 out of 3,745 
 
Bristol-Myers Squibb Compnay
 patents

Years Active: 2013-2026

Loading Chart...
Loading Chart...
Areas of Expertise:
PD-L1 Binding Polypeptides
Serum Albumin-Binding
Engineered Proteins
Tyrosine Kinase Receptors
Cancer Treatment
EGFR Binding
Imaging Techniques
Targeted Therapeutics
18 patents (USPTO):Explore Patents
1. 12534511 - SERUM ALBUMIN-BINDING FIBRONECTIN TYPE III DOMAINS (2026-01-27),
2. 12194110 - PD-L1 binding polypeptides for imaging (2025-01-14),
3. 11344639 - PET imaging with PD-L1 binding polypeptides (2022-05-31),
4. 11203630 - Serum albumin-binding fibronectin type III domains (2021-12-21),
5. 11173219 - PD-L1 binding polypeptides for imaging (2021-11-16),
6. 11149077 - Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR (2021-10-19),
7. 10934572 - Serum albumin binding molecules (2021-03-02),
8. 10781247 - Targeted therapeutics based on engineered proteins that bind EGFR (2020-09-22),
9. 10442851 - Serum albumin-binding fibronectin type III domains (2019-10-15),
10. 10406251 - PD-L1 binding polypeptides for imaging (2019-09-10),
11. 10221438 - Serum albumin binding molecules (2019-03-05),
12. 10221232 - Methods of treating cancer by administering IGF-IR binding molecules (2019-03-05),
13. 9920108 - Targeted therapeutics based on engineered proteins that bind EGFR (2018-03-20),
14. 9540424 - Serum albumin binding molecules (2017-01-10),
15. 9234028 - Targeted therapeutics based on engineered proteins that bind EGFR (2016-01-12),

Title: The Innovations of Inventor David Fabrizio

Introduction:

David Fabrizio, an esteemed inventor based in South Hamilton, MA, has made significant contributions to the field of biotechnology with a total of 16 patents to his name.

Latest Patents:

Among his latest patents is the groundbreaking invention titled "PET Imaging with PD-L1 Binding Polypeptides," which introduces novelFn3 domains that specifically bind to PD-L1. Additionally, he has patented "Serum Albumin-Binding Fibronectin Type III Domains," showcasing polypeptides that bind to serum albumin with unique south pole loop substitutions. These innovations pave the way for advanced diagnostics and therapeutic applications.

Career Highlights:

David Fabrizio is associated with the renowned company Bristol-Myers Squibb Company. His tenure at this respected organization has been marked by a dedication to pioneering research and development in the biotech industry.

Collaborations:

Throughout his career, David Fabrizio has collaborated with talented individuals such as Ray Camphausen and Paul E Morin. These collaborations have played a vital role in bringing his innovative ideas to fruition and advancing the field of biotechnology.

Conclusion:

Inventor David Fabrizio's impressive portfolio of patents underscores his commitment to pushing the boundaries of biotechnological innovation. His contributions continue to drive progress in the field, shaping the future of diagnostics and therapeutics.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…